BACKGROUND: Short-term studies have demonstrated that rapamycin or everolimus treatment decreases cyst formation and improves renal function in animal models of polycystic kidney disease (PKD). Autosomal dominant polycystic kidney disease (ADPKD) patients would likely require life-long treatment with rapamycin. METHODS: Male Han:SPRD rats with PKD (Cy/+) were treated with rapamycin (0.2 mg/kg/day IP) or vehicle from 1 to 12 months of age. Mean trough levels of rapamycin (ng/mL) were 6.6 +/- 0.1 at 8 weeks of age. Twelve-month-old littermates (+/+) were used as normal controls. RESULTS: Twelve-month-old male Cy/+ rats treated with the vehicle had a more than doubling of kidney volume, severe chronic renal failure, severe hypertension and increased heart weight compared to normal littermate controls (+/+). After rapamycin treatment, 12-month-old Cy/+ rats had markedly improved kidney volume, renal function, blood pressure and heart weight not statistically different from controls. Rapamycin reduced the cyst volume density (CVD) by 72%. Mammalian target of rapamycin (mTOR) activation in the heart, as evidenced by a marked increase in the phospho-S6 protein that was inhibited by rapamycin, was demonstrated in 12-month-old Cy/+ rats. CONCLUSION: In conclusion, long-term rapamycin treatment in Cy/+ rats results in a normalization of kidney volume, renal function, blood pressure and heart weight. The novel finding that rapamycin decreases hypertension, heart enlargement and mTOR signalling in the heart in PKD rats is reported. The only side effect of rapamycin treatment was an 11% decrease in body weight.
BACKGROUND: Short-term studies have demonstrated that rapamycin or everolimus treatment decreases cyst formation and improves renal function in animal models of polycystic kidney disease (PKD). Autosomal dominant polycystic kidney disease (ADPKD) patients would likely require life-long treatment with rapamycin. METHODS: Male Han:SPRD rats with PKD (Cy/+) were treated with rapamycin (0.2 mg/kg/day IP) or vehicle from 1 to 12 months of age. Mean trough levels of rapamycin (ng/mL) were 6.6 +/- 0.1 at 8 weeks of age. Twelve-month-old littermates (+/+) were used as normal controls. RESULTS: Twelve-month-old male Cy/+ rats treated with the vehicle had a more than doubling of kidney volume, severe chronic renal failure, severe hypertension and increased heart weight compared to normal littermate controls (+/+). After rapamycin treatment, 12-month-old Cy/+ rats had markedly improved kidney volume, renal function, blood pressure and heart weight not statistically different from controls. Rapamycin reduced the cyst volume density (CVD) by 72%. Mammalian target of rapamycin (mTOR) activation in the heart, as evidenced by a marked increase in the phospho-S6 protein that was inhibited by rapamycin, was demonstrated in 12-month-old Cy/+ rats. CONCLUSION: In conclusion, long-term rapamycin treatment in Cy/+ rats results in a normalization of kidney volume, renal function, blood pressure and heart weight. The novel finding that rapamycin decreases hypertension, heart enlargement and mTOR signalling in the heart in PKDrats is reported. The only side effect of rapamycin treatment was an 11% decrease in body weight.
Authors: T M Kennefick; M A Al-Nimri; T T Oyama; M M Thompson; F J Kelly; J G Chapman; S Anderson Journal: Kidney Int Date: 1999-12 Impact factor: 10.612
Authors: Jonathan M Shillingford; Noel S Murcia; Claire H Larson; Seng Hui Low; Ryan Hedgepeth; Nicole Brown; Chris A Flask; Andrew C Novick; David A Goldfarb; Albrecht Kramer-Zucker; Gerd Walz; Klaus B Piontek; Gregory G Germino; Thomas Weimbs Journal: Proc Natl Acad Sci U S A Date: 2006-03-27 Impact factor: 11.205
Authors: T Ecder; C L Edelstein; A B Chapman; A M Johnson; L Tison; E A Gill; G M Brosnahan; R W Schrier Journal: Nephrol Dial Transplant Date: 1999-05 Impact factor: 5.992
Authors: Patricia R Wahl; Andreas L Serra; Michel Le Hir; Klaus D Molle; Michael N Hall; Rudolf P Wüthrich Journal: Nephrol Dial Transplant Date: 2005-10-12 Impact factor: 5.992
Authors: Ming Wu; Patricia R Wahl; Michel Le Hir; Ying Wackerle-Men; Rudolf P Wuthrich; Andreas L Serra Journal: Kidney Blood Press Res Date: 2007-06-27 Impact factor: 2.687
Authors: Iram Zafar; Yunxia Tao; Sandor Falk; Kimberly McFann; Robert W Schrier; Charles L Edelstein Journal: Am J Physiol Renal Physiol Date: 2007-06-20
Authors: Kameswaran Ravichandran; Iram Zafar; Zhibin He; R Brian Doctor; Radu Moldovan; Adam E Mullick; Charles L Edelstein Journal: Hum Mol Genet Date: 2014-05-08 Impact factor: 6.150
Authors: Zlata Novalic; Annemieke M van der Wal; Wouter N Leonhard; Gudrun Koehl; Martijn H Breuning; Edward K Geissler; Emile de Heer; Dorien J M Peters Journal: J Am Soc Nephrol Date: 2012-02-16 Impact factor: 10.121
Authors: Jen X Xu; Tzong-Shi Lu; Suyan Li; Yong Wu; Lai Ding; Bradley M Denker; Joseph V Bonventre; Tianqing Kong Journal: Physiol Genomics Date: 2014-12-09 Impact factor: 3.107
Authors: Djalila Mekahli; Jean-Paul Decuypere; Eva Sammels; Kirsten Welkenhuyzen; Joost Schoeber; Marie-Pierre Audrezet; Anniek Corvelyn; Georges Dechênes; Albert C M Ong; Martijn J Wilmer; Lambertus van den Heuvel; Geert Bultynck; Jan B Parys; Ludwig Missiaen; Elena Levtchenko; Humbert De Smedt Journal: Pflugers Arch Date: 2013-11-06 Impact factor: 3.657